These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 3168141

  • 1. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice.
    Walton MI, Workman P.
    Cancer Chemother Pharmacol; 1988; 22(4):275-81. PubMed ID: 3168141
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M, Workman P.
    Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
    [Abstract] [Full Text] [Related]

  • 3. Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.
    Workman P, Walton MI.
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1307-10. PubMed ID: 6547936
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dual-function radiation sensitizers and bioreductive drugs: factors affecting cellular uptake and sensitizing efficiency in analogues of RSU 1069.
    Walling J, Stratford IJ, Adams GE, Stephens MA.
    Int J Radiat Biol Relat Stud Phys Chem Med; 1988 Apr; 53(4):641-9. PubMed ID: 3258298
    [Abstract] [Full Text] [Related]

  • 7. High uptake of RSU 1069 and its analogues melanotic melanomas.
    Walling JM, Deacon J, Holliday S, Stratford IJ.
    Cancer Chemother Pharmacol; 1989 Apr; 24(1):28-32. PubMed ID: 2541936
    [Abstract] [Full Text] [Related]

  • 8. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
    Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC.
    Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
    [Abstract] [Full Text] [Related]

  • 9. Induction of DNA strand breaks by RSU-1069, a nitroimidazole-aziridine radiosensitizer. Role of binding of both unreduced and radiation-reduced forms to DNA, in vitro.
    Silver AR, O'Neill P, Jenkins TC.
    Biochem Pharmacol; 1985 Oct 01; 34(19):3537-42. PubMed ID: 3902026
    [Abstract] [Full Text] [Related]

  • 10. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069.
    Hill RP, Gulyas S, Whitmore GF.
    Br J Cancer; 1986 Jun 01; 53(6):743-51. PubMed ID: 3755053
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic/pharmacokinetic evaluation of emesis induced by analogs of RSU 1069 and its control by antiemetic agents.
    Sebolt-Leopold JS, Vincent PW, Beningo KA, Elliott WL, Leopold WR, Heffner TG, Wiley JN, Stier MA, Suto MJ.
    Int J Radiat Oncol Biol Phys; 1992 Jun 01; 22(3):549-51. PubMed ID: 1531213
    [Abstract] [Full Text] [Related]

  • 12. RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.
    Adams GE, Ahmed I, Sheldon PW, Stratford IJ.
    Int J Radiat Oncol Biol Phys; 1984 Sep 01; 10(9):1653-6. PubMed ID: 6548211
    [Abstract] [Full Text] [Related]

  • 13. Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.
    Cobb LM, Nolan J, Butler SA.
    Br J Cancer; 1990 Dec 01; 62(6):915-8. PubMed ID: 2257219
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI, Workman P.
    J Pharmacol Exp Ther; 1993 May 01; 265(2):938-47. PubMed ID: 8496834
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins.
    Jenkins TC, Naylor MA, O'Neill P, Threadgill MD, Cole S, Stratford IJ, Adams GE, Fielden EM, Suto MJ, Stier MA.
    J Med Chem; 1990 Sep 01; 33(9):2603-10. PubMed ID: 2391699
    [Abstract] [Full Text] [Related]

  • 16. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
    Stratford IJ, Adams GE, Godden J, Howells N.
    Int J Radiat Biol; 1989 Mar 01; 55(3):411-22. PubMed ID: 2564037
    [Abstract] [Full Text] [Related]

  • 17. Oncogenic transforming potential of nitroimidazole radiosensitizers.
    Hall EJ, Hei TK.
    Int J Radiat Oncol Biol Phys; 1989 May 01; 16(5):1231-4. PubMed ID: 2523882
    [Abstract] [Full Text] [Related]

  • 18. Preclinical pharmacokinetics of benznidazole.
    Workman P, White RA, Walton MI, Owen LN, Twentyman PR.
    Br J Cancer; 1984 Sep 01; 50(3):291-303. PubMed ID: 6466543
    [Abstract] [Full Text] [Related]

  • 19. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice.
    Cole S, Stratford IJ, Bowler J, Nolan J, Wright EG, Lorimore SA, Adams GE.
    Int J Radiat Oncol Biol Phys; 1991 Jul 01; 21(2):387-95. PubMed ID: 2061115
    [Abstract] [Full Text] [Related]

  • 20. CB 1954 revisited. I. Disposition kinetics and metabolism.
    Workman P, White RA, Talbot K.
    Cancer Chemother Pharmacol; 1986 Jul 01; 16(1):1-8. PubMed ID: 3940216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.